IGF1R deficiency in vascular smooth muscle cells impairs myogenic autoregulation and cognition in mice

Front Aging Neurosci. 2024 Feb 15:16:1320808. doi: 10.3389/fnagi.2024.1320808. eCollection 2024.

Abstract

Introduction: Cerebrovascular pathologies contribute to cognitive decline during aging, leading to vascular cognitive impairment and dementia (VCID). Levels of circulating insulin-like growth factor 1 (IGF-1), a vasoprotective hormone, decrease during aging. Decreased circulating IGF-1 in animal models leads to the development of VCID-like symptoms, but the cellular mechanisms underlying IGF-1-deficiency associated pathologies in the aged cerebrovasculature remain poorly understood. Here, we test the hypothesis that vascular smooth muscle cells (VSMCs) play an integral part in mediating the vasoprotective effects of IGF-1.

Methods: We used a hypertension-based model of cerebrovascular dysfunction in mice with VSMC-specific IGF-1 receptor (Igf1r) deficiency and evaluated the development of cerebrovascular pathologies and cognitive dysfunction.

Results: VSMC-specific Igf1r deficiency led to impaired cerebral myogenic autoregulation, independent of blood pressure changes, which was also associated with impaired spatial learning and memory function as measured by radial arm water maze and impaired motor learning measured by rotarod. In contrast, VSMC-specific IGF-1 receptor knockdown did not lead to cerebral microvascular rarefaction.

Discussion: These studies suggest that VSMCs are key targets for IGF-1 in the context of cerebrovascular health, playing a role in vessel stability alongside other cells in the neurovascular unit, and that VSMC dysfunction in aging likely contributes to VCID.

Keywords: aging; brain; cerebrovascular aging; insulin-like growth factor-1; intracerebral hemorrhage; microhemorrhage; vascular cognitive impairment.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Institutes of Health (R01AG070915, R03AG070479, K01AG073614, and R01EY019494) including cores supported as part of (1P20GM125528, 5P30EY021725-10, P30CA225520, and 5P30GM122744), American Heart Association (AHA941290), Hevolution Foundation, Oklahoma Shared Clinical and Translational Resources (U54GM104938), Geroscience Training Program in Oklahoma (T32AG052363), the Oklahoma Nathan Shock Center (P30AG050911), Cellular and Molecular GeroScience CoBRE (1P20GM125528), Presbyterian Health Foundation, Oklahoma Center for Adult Stem Cell Research, and the Oklahoma Center for the Advancement of Science and Technology. Funding agencies had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.